search
Back to results

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
TH9507
Sponsored by
Theratechnologies
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or postmenopausal or surgically sterilized female subjects, 50 years of age or older;
  • Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association;
  • Diagnosis of type 2 diabetes for at least 3 months before screening;
  • Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening;
  • Screening and pre-randomization glycosylated hemoglobin (HbA1c) <10.0%, according to central laboratory;
  • Body mass index (BMI) between 25 and 38 kg/m2
  • Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements;
  • Signed informed consent.

Exclusion Criteria:

  • Serum creatinine >2 mg/dL;
  • Fasting triglycerides >1000 mg/dL;
  • Albuminuria >200 mg/24 hours;
  • Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male);
  • Use of oral or parenteral glucocorticoids in the 30 days before screening;
  • Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months;
  • Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization;
  • History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements;
  • Subjects with a major surgical operation during the 30 days before screening;
  • Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma;
  • Current cancer or history of cancer, except non-melanomatous skin cancer;
  • Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening;
  • Subjects with clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor);
  • Subjects with allergy to synthetic growth hormone products or their excipients;
  • Subjects who had previously received growth hormones in any clinical trial;
  • Participation in a trial of an experimental drug or device within 90 days before screening.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Change from baseline in relative insulin response

    Secondary Outcome Measures

    Change from baseline in glycosylated hemoglobin (HbA1c)
    Change in mean daily serum glucose concentrations
    Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter
    Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents
    Number of subjects with a change in the control of diabetes

    Full Information

    First Posted
    December 17, 2010
    Last Updated
    December 20, 2010
    Sponsor
    Theratechnologies
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01264497
    Brief Title
    Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
    Official Title
    A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2010
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2002 (undefined)
    Primary Completion Date
    November 2002 (Actual)
    Study Completion Date
    November 2002 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Theratechnologies

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    55 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    TH9507
    Intervention Description
    1 and 2 mg, sc daily for 12 weeks
    Primary Outcome Measure Information:
    Title
    Change from baseline in relative insulin response
    Secondary Outcome Measure Information:
    Title
    Change from baseline in glycosylated hemoglobin (HbA1c)
    Title
    Change in mean daily serum glucose concentrations
    Description
    Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter
    Title
    Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents
    Title
    Number of subjects with a change in the control of diabetes

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or postmenopausal or surgically sterilized female subjects, 50 years of age or older; Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association; Diagnosis of type 2 diabetes for at least 3 months before screening; Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening; Screening and pre-randomization glycosylated hemoglobin (HbA1c) <10.0%, according to central laboratory; Body mass index (BMI) between 25 and 38 kg/m2 Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements; Signed informed consent. Exclusion Criteria: Serum creatinine >2 mg/dL; Fasting triglycerides >1000 mg/dL; Albuminuria >200 mg/24 hours; Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male); Use of oral or parenteral glucocorticoids in the 30 days before screening; Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months; Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization; History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements; Subjects with a major surgical operation during the 30 days before screening; Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma; Current cancer or history of cancer, except non-melanomatous skin cancer; Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening; Subjects with clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor); Subjects with allergy to synthetic growth hormone products or their excipients; Subjects who had previously received growth hormones in any clinical trial; Participation in a trial of an experimental drug or device within 90 days before screening.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    28617838
    Citation
    Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017.
    Results Reference
    derived

    Learn more about this trial

    Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

    We'll reach out to this number within 24 hrs